Opportunities in the hyperhidrosis treatment market have evolved through a number of stages i.e. Lucintel has found the future of this market to be promising; the hyperhidrosis treatment market is expected to reach $XX billion by 2028 with a CAGR of 4% to 6%. In this market, Btulinumtoxin A is expected to remain the largest treatment type, and hospitals segment is expected to remain the largest...